Suppr超能文献

CRISPR/Cas9 相关技术在肝脏疾病中的应用:从可行性到未来的多样性。

CRISPR/Cas9-related technologies in liver diseases: from feasibility to future diversity.

机构信息

Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, 81 Meishan Road, Hefei 230032, Anhui Province, China.

Institute for Liver Diseases of Anhui Medical University, Anhui Medical University, Hefei 230032, China.

出版信息

Int J Biol Sci. 2020 Jun 1;16(13):2283-2295. doi: 10.7150/ijbs.33481. eCollection 2020.

Abstract

Liver diseases are one of the leading causes of mortality in the world, mainly caused by different etiological agents, alcohol consumption, viruses, drug intoxication, and malnutrition. The maturation of gene therapy has heralded new avenues for developing effective interventions for these diseases. Derived from a remarkable microbial defense system, clustered regularly interspaced short palindromic repeats/CRISPR-associated proteins 9 system (CRISPR/Cas9 system) is driving innovative applications from basic biology to biotechnology and medicine. Recently, the mutagenic function of CRISPR/Cas9 system has been widely adopted for genome and disease research. In this review, we describe the development and applications of CRISPR/Cas9 system on liver diseases for research or translational applications, while highlighting challenges as well as future avenues for innovation.

摘要

肝脏疾病是世界范围内主要的致死病因之一,主要由不同的病因、酒精摄入、病毒、药物中毒和营养不良引起。基因治疗的成熟为这些疾病的有效干预措施的开发开辟了新的途径。来源于一个非凡的微生物防御系统,成簇规律间隔短回文重复序列/CRISPR 相关蛋白 9 系统(CRISPR/Cas9 系统)正在推动从基础生物学到生物技术和医学的创新应用。最近,CRISPR/Cas9 系统的诱变功能已被广泛应用于基因组和疾病研究。在这篇综述中,我们描述了 CRISPR/Cas9 系统在肝脏疾病的研究或转化应用方面的发展和应用,同时强调了挑战以及未来的创新途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1320/7378651/8ef4dc7d2f85/ijbsv16p2283g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验